Column Capital Advisors’s Sage Therapeutics SAGE Stock Holding History

Column Capital Advisors’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-27	Closed	-$1K	–	839
2020 Q2	$1K	Buy	+27	New	+$980	﹤0.01%	786

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Column Capital Advisors's SAGE Position: Q3 2020 in Review

Column Capital Advisors sold out of Sage Therapeutics (SAGE) in Q3 2020, closing a stake of 27 shares — an estimated $1K sold.

Column Capital Advisors first reported a position in SAGE in Q2 2020 and held it in 1 quarter. The position peaked at $1K in Q2 2020. 231 funds tracked by Wall St. Rank hold SAGE as of Q3 2020.

Column Capital Advisors reported no remaining Sage Therapeutics position as of Q3 2020 after selling out during the quarter.
Column Capital Advisors sold 27 Sage Therapeutics shares in Q3 2020, an estimated $1K.
Column Capital Advisors first reported a position in Sage Therapeutics in Q2 2020 and held it in 1 quarter.
Column Capital Advisors's Sage Therapeutics position peaked at $1K in Q2 2020.
231 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2020.

Based on Column Capital Advisors's 13F filing for Q3 2020, filed 12 Nov 2020.